192 results on '"Paterson, Yvonne"'
Search Results
2. Supplementary Table S1 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
3. Supplementary Fig S1 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
4. Supplementary Table S5 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
5. Supplementary Figure S2 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
6. Supplementary Table S2 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
7. Supplementary Figure S2 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
8. Supplementary Table S3 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
9. Data from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
10. Supplementary Table S6 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
11. Supplementary Table S4 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
12. Data from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
13. Supplementary Table S5 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
14. Supplementary Data from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
15. CCR Translation on this Article from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
16. CCR Translation on this Article from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
17. Supplementary Data from A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
18. Supplementary Figure 1 Legend from Immunoediting Sculpts Tumor Epitopes during Immunotherapy
19. Supplementary Figure 1 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
20. Supplementary Table 1 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
21. Data from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
22. Supplementary Figure Legends 1-3 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
23. Supplementary Figure Legends 1-3 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
24. Supplementary Figure 3 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
25. Supplementary Figure 1 Legend from Immunoediting Sculpts Tumor Epitopes during Immunotherapy
26. Data from Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature
27. Supplementary Figure 1 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
28. Supplementary Figure 3 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
29. Supplementary Figure 2 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
30. Supplementary Figure 1 from Immunoediting Sculpts Tumor Epitopes during Immunotherapy
31. Supplementary Figure 1 from Immunoediting Sculpts Tumor Epitopes during Immunotherapy
32. Supplementary Table 1 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
33. Data from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
34. Supplementary Figures 1-4 from Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature
35. Supplementary Figure 2 from High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
36. Data from Immunoediting Sculpts Tumor Epitopes during Immunotherapy
37. Immunoediting
38. Immunoediting
39. Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies
40. Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma
41. Listeria monocytogenes and Its Products as Agents for Cancer Immunotherapy
42. Immunoediting
43. Chapter 1 Multiple Effector Mechanisms Induced by Recombinant Listeria monocytogenes Anticancer Immunotherapeutics
44. Anticancer Vaccine Strategies
45. Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis
46. Immunotherapeutic Strategies against Cancer using Listeria monocytogenes as a Vector for Tumor Antigens
47. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
48. The Role of B Cells in Mouse Hepatitis Virus Infection and Pathology
49. Pathology of MHV-A59 Infection in ß2 Microglobulin Negative Mice
50. Negative regulation of IFNAR1/2 Signaling by USP18 is required for immunity to Listeria monocytogenes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.